A powerful new study on the failure of mammograms to protect women against breast cancer, curiously absent from mainstream news health reporting, was published this month in The European Journal of Public Health, and is forcing the scientific and medical community, policy makers and the public at large to ask the question: can the now worldwide practice of mass breast screenings in healthy (asymptomatic) populations be justified when they increase the incidence of localized stage ‘cancers’ without reducing the incidence of advanced cancers?
Titled, “Trends in breast cancer stage distribution before, during and after introduction of a screening programme in Norway,” the study found that based on a population sample of 1.8 million Norwegian women, diagnosed with breast cancer 1987-2010,
“The annual incidence of localized breast cancer among women aged 50–69 years rose from 63.9 per 100 000 before the introduction of screening to 141.2 afterwards, corresponding to a ratio of 2.21 (95% confidence interval: 2.10; 2.32). The incidence of more advanced cancers increased from 86.9 to 117.3 per 100 000 afterwards, corresponding to a 1.35 (1.29; 1.42)-fold increase. Advanced cancers also increased among younger women not eligible for screening, whereas their incidence of localized cancers remained nearly constant.” [emphasis added]
In other words, enrollment in Norway’s breast screening program increased the chance of being diagnosed with an early-stage breast ‘cancer’ diagnoses by 221%, and more disturbingly, increased the chance of being diagnosed with an advanced (lethal) breast cancer by 35% — exactly opposite what would be expected if the mammograms were actually catching malignant tumors early, which would imply the incidence of the more lethal, late stage cancers would be lower and not higher. (see: see scientist’s description of how breast cancer overdiagnosis occurs on GreenMedTV.com)
The study concluded with the following summarization:
“Conclusion: Incidence of localized breast cancer increased significantly among women aged 50–69 years old after introduction of screening, while the incidence of more advanced cancers was not reduced in the same period when compared to the younger unscreened age group.”
While not discussed in depth within the article, their results indicate that breast screening causes profound numbers of overdiagnosis, and because of the ‘overtreatment’ (and mistreatment) that results from this, produces excess morbidity and mortality in screened women as a result. Indeed, one of the most dramatic revelations of our time occurred last year when a National Cancer Institute commissioned expert panel concluded that so-called ‘early stage cancers’ such as Ductal Carcinoma In Situ (DCIS) are not cancer at all, but benign or indolent growths. This implies that millions of women were wrongly diagnosed with ‘breast cancer’ over the past 30 years who would have been better off left undiagnosed and untreated.
View full post